Benjamin Friedrichson1, Haitham Mutlak2,3, Kai Zacharowski2, Florian Piekarski2. 1. Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. Benjamin.Friedrichson@kgu.de. 2. Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. 3. Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, SANA Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach am Main, Germany.
Abstract
BACKGROUND: Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature METHODS: Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. RESULTS: In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. CONCLUSIONS: ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.
BACKGROUND: Extracorporeal life support (ECLS) has become an integral part of modern intensive therapy. The choice of support mode depends largely on the indication. Patients with respiratory failure are predominantly treated with a venovenous (VV) approach. We hypothesized that mortality in Germany in ECLS therapy did not differ from previously reported literature METHODS: Inpatient data from Germany from 2007 to 2018 provided by the Federal Statistical Office of Germany were analysed. The international statistical classification of diseases and related health problems codes (ICD) and process keys (OPS) for extracorporeal membrane oxygenation (ECMO) types, acute respiratory distress syndrome (ARDS) and hospital mortality were used. RESULTS: In total, 45,647 hospitalized patients treated with ECLS were analysed. In Germany, 231 hospitals provided ECLS therapy, with a median of 4 VV-ECMO and 9 VA-ECMO in 2018. Overall hospital mortality remained higher than predicted in comparison to the values reported in the literature. The number of VV-ECMO cases increased by 236% from 825 in 2007 to 2768 in 2018. ARDS was the main indication for VV-ECMO in only 33% of the patients in the past, but that proportion increased to 60% in 2018. VA-ECMO support is of minor importance in the treatment of ARDS in Germany. The age distribution of patients undergoing ECLS has shifted towards an older population. In 2018, the hospital mortality decreased in VV-ECMO patients and VV-ECMO patients with ARDS to 53.9% (n = 1493) and 54.4% (n = 926), respectively. CONCLUSIONS:ARDS is a severe disease with a high mortality rate despite ECLS therapy. Although endpoints and timing of the evaluations differed from those of the CESAR and EOLIA studies and the Extracorporeal Life Support Organization (ELSO) Registry, the reported mortality in these studies was lower than in the present analysis. Further prospective analyses are necessary to evaluate outcomes in ECMO therapy at the centre volume level.
Entities:
Keywords:
ARDS; ECMO; Extracorporeal life support; Mortality; OPS
Authors: Johannes Herrmann; Christopher Lotz; Christian Karagiannidis; Steffen Weber-Carstens; Stefan Kluge; Christian Putensen; Andreas Wehrfritz; Karsten Schmidt; Richard K Ellerkmann; Daniel Oswald; Gösta Lotz; Viviane Zotzmann; Onnen Moerer; Christian Kühn; Matthias Kochanek; Ralf Muellenbach; Matthias Gaertner; Falk Fichtner; Florian Brettner; Michael Findeisen; Markus Heim; Tobias Lahmer; Felix Rosenow; Nils Haake; Philipp M Lepper; Peter Rosenberger; Stephan Braune; Mirjam Kohls; Peter Heuschmann; Patrick Meybohm Journal: Crit Care Date: 2022-06-28 Impact factor: 19.334
Authors: Jonna D Clark; Harris P Baden; Emily R Berkman; Erica Bourget; Thomas V Brogan; Jane L Di Gennaro; Ardith Z Doorenbos; D Michael McMullan; Joan S Roberts; Jessica M Turnbull; Benjamin S Wilfond; Mithya Lewis-Newby Journal: Front Pediatr Date: 2022-05-19 Impact factor: 3.569
Authors: Eugen Widmeier; Tobias Wengenmayer; Sven Maier; Christoph Benk; Viviane Zotzmann; Dawid L Staudacher; Alexander Supady Journal: Artif Organs Date: 2022-07-20 Impact factor: 2.663
Authors: Sebastian D Sahli; Alexander Kaserer; Donat R Spahn; Markus J Wilhelm; Julia Braun; Maximilian Halbe; Yuliya Dahlem; Muriel A Spahn; Julian Rössler; Bernard Krüger; Francesco Maisano Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005
Authors: Mazen Odish; Cassia Yi; Christopher Tainter; Samira Najmaii; Julio Ovando; Laura Chechel; Jerry Lipinski; Alex Ignatyev; Alexander Pile; Yun Yeong Jang; Tuo Lin; Xin M Tu; Michael Madani; Mitul Patel; Angela Meier; Travis Pollema; Robert L Owens Journal: Crit Care Explor Date: 2021-06-15
Authors: Ryszard Gawda; Maciej Piwoda; Maciej Marszalski; Katarzyna Lyp; Jolanta Piwoda; Magdalena Maj; Maciej Gawor; Maciej Molsa; Marek Pietka; Tomasz Czarnik Journal: Healthcare (Basel) Date: 2022-02-22